Saxenda Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Liraglutide

Indications/Uses

Adjunct to a reduced-calorie diet & increased physical activity for wt management in adults w/ initial BMI of ≥30 kg/m² (obese) or ≥27 kg/m² to <30 kg/m² (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea. Adjunct to a healthy nutrition & increased physical activity for wt management in adolescents ≥12 yr w/ obesity (BMI corresponding to ≥30 kg/m² for adults by international cut-off points) & body wt >60 kg.

Click to view Saxenda detailed prescribing information

Dosage/Direction for Use

SC Adult & adolescent ≥12 yr Initially, 0.6 mg once daily. Increase to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk interval to improve GI tolerability. Maintenance dose: 3 mg daily.

Click to view Saxenda detailed prescribing information

Overdosage

View Saxenda overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

Click to view Saxenda detailed prescribing information

Special Precautions

Do not administer as IV/IM. Do not use as substitute for insulin in patients w/ DM. Not recommended in patients w/ CHF NYHA class IV; treatment w/ other products for wt management; obesity secondary to endocrinological or eating disorders or to treatment w/ medicinal products that may cause wt gain; inflammatory bowel disease & diabetic gastroparesis. Discontinue & do not restart treatment if pancreatitis & acute pancreatitis is confirmed. Cholelithiasis & cholecystitis. Thyroid disease. Monitor heart rate regularly. Discontinue if clinically relevant sustained increase in resting heart rate is experienced. Risk of dehydration & fluid depletion. Do not use in combination w/ another GLP-1 receptor agonist. Concomitant use w/ insulin &/or sulfonylurea. May affect ability to drive & use machines. Mild or moderate hepatic impairment. Not recommended in patients w/ severe hepatic & renal impairment (CrCl <30 mL/min) & ESRD. Not to be used during pregnancy & lactation. Childn <12 yr. Elderly ≥75 yr.

Click to view Saxenda detailed prescribing information

Use In Pregnancy & Lactation

Click to view Saxenda detailed prescribing information

Adverse Reactions

Headache; nausea, vomiting, diarrhoea, constipation. Hypoglycaemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, upper abdominal pain, flatulence, eructation, abdominal distension; cholelithiasis; inj site reactions, asthenia, fatigue; increased lipase/amylase.

Click to view Saxenda detailed prescribing information

Drug Interactions

Increased risk of hypoglycemia w/ insulin &/or sulfonylureas. Concomitant use w/ warfarin & other coumarin derivatives. Decreased C_max & delayed t_max of paracetamol (acetaminophen), atorvastatin, OCs. Increased C_max of griseofulvin. Reduced AUC, C_max & delayed t_max of digoxin & lisinopril.

Click to view Saxenda detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Saxenda detailed prescribing information

Storage

View Saxenda storage conditions for details to ensure optimal shelf-life.

Description

View Saxenda description for details of the chemical structure and excipients (inactive components).

Action

View Saxenda mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Anti-Obesity Agents / Antidiabetic Agents

ATC Classification

A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.

Regulatory Classification

Patient Counseling Information

View Saxenda patient counselling information

Presentation/Packing

Form

Saxenda soln for inj 6 mg/mL

Packing/Price

(type 1 glass cartridge w/ bromobutyl plunger & stopper) 3 mL x 3 × 1's

Saxenda

liraglutide

Manufacturer:

Novo Nordisk

Distributor:

Novo Nordisk